A Randomized Trial of PHOTOdynamic Surgery in Non–Muscle-Invasive Bladder Cancer-Reference-Cited by-同舟云学术

A Randomized Trial of PHOTOdynamic Surgery in Non–Muscle-Invasive Bladder Cancer

Published:2022-09-27 Issue:10 Volume:1 Page:
ISSN:2766-5526
Container-title:NEJM Evidence
language:en
Short-container-title:NEJM Evidence

Author:

Heer Rakesh¹,Lewis Rebecca²,Vadiveloo Thenmalar³,Yu Ge¹,Mariappan Paramananthan⁴,Cresswell Joanne⁵,McGrath John⁶,Nabi Ghulam⁷,Mostafid Hugh⁸,Lazarowicz Henry⁹,Kelly John¹⁰,Duncan Anne³,Penegar Steven²,Breckons Matt¹,Wilson Laura¹,Clark Emma¹,Feber Andy¹⁰,Orozco-Leal Giovany¹,Tandogdu Zafer¹⁰,Taylor Ernest¹¹,N’Dow James¹²,Norrie John¹³,Ramsay Craig¹⁴,Rice Stephen¹,Vale Luke¹,MacLennan Graeme³,Hall Emma²

Affiliation:

1. Newcastle University, Newcastle upon Tyne, United Kingdom

2. The Institute of Cancer Research, London

3. Centre for Healthcare Randomised Trials, University of Aberdeen, Aberdeen, United Kingdom

4. Edinburgh Bladder Cancer Surgery, Department of Urology, Western General Hospital, Edinburgh

5. South Tees Hospitals NHS Trust, Middlesbrough, United Kingdom

6. Royal Devon and Exeter Hospital NHS Trust, Exeter, United Kingdom

7. University of Dundee, Dundee, United Kingdom

8. Basingstoke and North Hampshire NHS Foundation Trust, Basingstoke, United Kingdom

9. Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom

10. University College London Hospitals NHS Foundation Trust, London

11. PHOTO Trial patient representative, United Kingdom

12. Academic Urology Unit, University of Aberdeen, Aberdeen, United Kingdom

13. Edinburgh Clinical Trials Unit, Edinburgh University, Edinburgh

14. Health Services Research Unit, University of Aberdeen, Aberdeen, United Kingdom

Publisher

Massachusetts Medical Society

Reference32 articles.

1. IARC CancerBase No. 15

2. European Association of Urology. EAU Guidelines. Presented at the 36th Annual EAU Congress Milan July 8–12 2021.

3. Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials

4. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline

5. National Institute for Health and Care Excellence. Bladder Cancer: Diagnosis and Management. National Institute for Health and Care Excellence. February 25 2015 (https://www.nice.org.uk/guidance/ng2/chapter/Update-information).

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intravesical hexyl-aminolevulinate used to detect upper tract carcinoma in situ during surveillance ureteroscopy: A case report and review;Urology Case Reports;2024-09

2. European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)—A Summary of the 2024 Guidelines Update;European Urology;2024-08

3. Optimizing cystoscopy and TURBT: enhanced imaging and artificial intelligence;Nature Reviews Urology;2024-07-09

4. Perioperative Outcomes and Trends in Transurethral Resection of Bladder Tumors with Photodynamic Diagnosis: Results from the GeRmAn Nationwide Inpatient Data Study;Journal of Clinical Medicine;2024-06-17

5. From Detection to Cure – Emerging Roles for Urinary Tumor DNA (utDNA) in Bladder Cancer;Current Oncology Reports;2024-06-05